These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

782 related articles for article (PubMed ID: 16156677)

  • 41. Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.
    Löhle M; Reichmann H
    BMC Neurol; 2011 Sep; 11():112. PubMed ID: 21939547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Old Drugs, New Delivery Systems in Parkinson's Disease.
    Gupta HV; Lyons KE; Pahwa R
    Drugs Aging; 2019 Sep; 36(9):807-821. PubMed ID: 31161581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    McIntosh E; Kent S; Gray A; Clarke CE; Williams A; Jenkinson C; Ives N; Patel S; Rick C; Wheatley K; Gray R;
    Mov Disord; 2021 Sep; 36(9):2136-2143. PubMed ID: 33960511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson's Disease: Beyond the Primary Mechanism of Action.
    Rinaldi D; Alborghetti M; Bianchini E; Sforza M; Galli S; Pontieri FE
    Curr Neuropharmacol; 2023; 21(5):1214-1223. PubMed ID: 36065929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 'Bad guys' among the antiparkinsonian drugs.
    Pirtosek Z
    Psychiatr Danub; 2009 Mar; 21(1):114-8. PubMed ID: 19270634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacological treatment of Parkinson's disease.
    Münchau A; Bhatia KP
    Postgrad Med J; 2000 Oct; 76(900):602-10. PubMed ID: 11009573
    [No Abstract]   [Full Text] [Related]  

  • 50. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rasagiline: a review of its use in the management of Parkinson's disease.
    Oldfield V; Keating GM; Perry CM
    Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson's disease are dependent on frontal function.
    Murakami H; Okumura M; Ozawa M; Mimori M; Maku T; Shiraishi T; Kitagawa T; Takatsu H; Sato T; Komatsu T; Sakai K; Umehara T; Omoto S; Mitsumura H; Iguchi Y
    Neurol Sci; 2023 Mar; 44(3):913-918. PubMed ID: 36376554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease.
    Sieradzan K; Channon S; Ramponi C; Stern GM; Lees AJ; Youdim MB
    J Clin Psychopharmacol; 1995 Aug; 15(4 Suppl 2):51S-59S. PubMed ID: 7593732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Initial treatment of Parkinson's disease].
    Kulisevsky J; López-Villegas D
    Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug treatment of Parkinson's disease.
    Quinn N
    BMJ; 1995 Mar; 310(6979):575-9. PubMed ID: 7888935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rasagiline for the treatment of Parkinson's disease: an update.
    Stocchi F; Fossati C; Torti M
    Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current Pharmacological Treatment for Parkinson's Disease].
    Saitoh Y; Takahashi K
    Brain Nerve; 2023 May; 75(5):441-449. PubMed ID: 37194511
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Medical and surgical treatment of Parkinson's disease].
    Defebvre L; Moreau C
    Presse Med; 2017 Mar; 46(2 Pt 1):218-224. PubMed ID: 28279509
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Other pharmacological treatments for motor complications and dyskinesias.
    Waters C
    Mov Disord; 2005; 20 Suppl 11():S38-44. PubMed ID: 15822104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.